Company Description
Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States.
The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.
Its lead product candidate is TYRA-300, which is in Phase 1/2 clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors.
The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in Phase 1 clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma.
The company was incorporated in 2018 and is headquartered in Carlsbad, California.
| Country | United States |
| Founded | 2018 |
| IPO Date | Sep 15, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 49 |
| CEO | Dr. Todd Harris Ph.D. |
Contact Details
Address: 2656 State Street Carlsbad, California 92008 United States | |
| Phone | (619) 728-4760 |
| Website | tyra.bio |
Stock Details
| Ticker Symbol | TYRA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0001863127 |
| CUSIP Number | 90240B106 |
| ISIN Number | US90240B1061 |
| Employer ID | 83-1476348 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Todd Harris Ph.D. | Co-Founder, President, Chief Executive Officer, Secretary, Treasurer and Director |
| Daniel Bensen | Co-Founder and Chief Operating Officer |
| Ali D. Fawaz J.D. | General Counsel and Secretary |
| Alan Fuhrman | Chief Financial Officer |
| Dr. Robert L. Hudkins Ph.D. | Chief Technology Officer |
| Dr. Ronald V. Swanson Ph.D. | Chief Scientific Officer |
| Sarah Honig | Vice President of Corporate Development and Strategy |
| Dr. Hiroomi Tada M.D., Ph.D. | Chief Medical Officer |
| Dr. Piyush R. Patel Ph.D. | Chief Development Officer |
| Amy Conrad | Investor Contact |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 9, 2024 | 10-Q | Quarterly Report |
| May 9, 2024 | 8-K | Current Report |
| May 7, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| May 7, 2024 | 8-K | Current Report |
| Apr 22, 2024 | EFFECT | Notice of Effectiveness |
| Apr 18, 2024 | ARS | Filing |
| Apr 18, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 18, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 5, 2024 | PRE 14A | Other preliminary proxy statements |
| Mar 19, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |